Avangio 400 mg Injection
  1. Home
  2. Pharma Products
  3. Plasmagen BioSciences Pvt Ltd
  4. Avangio 400 mg Injection

Avangio 400 mg Injection

Avangio 400 mg Injection contains bevacizumab, a monoclonal antibody used in the treatment of several types of cancer. It works by blocking vascular endothelial growth factor (VEGF), which helps reduce the formation of blood vessels that supply tumors. The medicine is administered as an intravenous infusion by a qualified healthcare professional.

BUY NOW

Category

Avangio 400 mg Injection contains 400 mg of bevacizumab in a 16 mL vial and is manufactured by PlasmaGen Biosciences Pvt Ltd. It may be used as part of treatment regimens for colorectal cancer, non-small cell lung cancer, renal cell carcinoma, ovarian cancer, cervical cancer, and glioblastoma. Bevacizumab binds to VEGF and inhibits tumor-associated blood vessel formation, which can help slow tumor growth. The product should be administered by intravenous infusion and stored refrigerated at 2°C to 8°C without freezing or shaking.

Technical Specification

Specification Details
Active Ingredient Bevacizumab 400 mg
Concentration 25 mg/mL
Presentation 16 mL Single-Dose Vial
Dosage Form Concentrate for Solution for Infusion
Route of Administration Intravenous Infusion
Storage 2°C to 8°C

Product Also Known As

Avangio 400 mg Injection, Avangio 400 mg/16 mL Injection, Avangio Bevacizumab 400 mg Injection, Bevacizumab 400 mg Injection, Bevacizumab 400 mg Infusion, Bevacizumab Oncology Injection

Related products